Abstract
This study aimed to develop nomograms to predict long-term overall survival and cancer-specific survival in patients with head and neck squamous cell carcinoma (HNSCC). We conducted prognostic analyses and developed nomograms predicting survival outcome using HNSCC patient data collected from the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute. An external dataset of 219 patients was used to validate the nomograms. Of 36,179 HNSCC patients, 9,627 (26.6%) died from HNSCC and 4,229 (11.7%) died from other causes. Median follow-up was 28 months (1-107 months). Nomograms predicting overall survival (OS) and cancer-specific survival (CSS) were developed according to 10 clinicopathologic factors (age, race, sex, tumor site, tumor grade, surgery, radiotherapy and TNM stage), with concordance indexes (C-indexes) of 0.719 and 0.741, respectively. External validation C-indexes were 0.709 and 0.706 for OS and CSS, respectively. Our results suggest that we successfully developed nomograms predicting five- and eight-year HNSCC patient OS and CSS with high accuracy. These nomograms could help clinicians tailor surgical, adjuvant therapeutic and follow-up strategies to more effectively treat HNSCC patients.
Highlights
Head and neck squamous cell carcinoma (HNSCC) is the most common malignant head and neck tumor
While deaths resulting from other causes (DROC) are often related to cancer-specific mortality (CSM), measuring cancer-specific survival (CSS), rather than overall survival (OS), will more accurately describe patient survival due to HNSCC directly
We aimed to develop HNSCC nomograms predicting long-term OS and CSS based on multiple clinicopathologic factors, as well as TNM stage, to improve individual patient treatments and follow-up strategies
Summary
Head and neck squamous cell carcinoma (HNSCC) is the most common malignant head and neck tumor. Due to clinicopathologic heterogeneity and relatively high malignancy, three- and five-year HNSCC patient OS rates range from 54.0% to 93% and 46.2% to 82%, respectively [4, 5]. Accurate estimates of HNSCC patient prognoses based on clinicopathologic factors would help clinicians provide appropriate individual treatments. HNSCC patients are at high risk of death from other factors such as liver diseases, secondary cancers and chemoradiotherapeutic toxicity [6, 7]. While deaths resulting from other causes (DROC) are often related to cancer-specific mortality (CSM), measuring CSS, rather than OS, will more accurately describe patient survival due to HNSCC directly
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
